X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (27) 27
female (21) 21
index medicus (21) 21
middle aged (19) 19
male (18) 18
rheumatology (18) 18
adult (15) 15
arthritis, rheumatoid - drug therapy (13) 13
tumor necrosis factor-alpha - antagonists & inhibitors (13) 13
treatment outcome (12) 12
antibodies, monoclonal - therapeutic use (11) 11
double-blind method (11) 11
rheumatoid arthritis (11) 11
aged (9) 9
antirheumatic agents - therapeutic use (9) 9
abridged index medicus (8) 8
drug therapy (7) 7
infliximab (7) 7
methotrexate (7) 7
methotrexate - therapeutic use (7) 7
antibodies, monoclonal - administration & dosage (6) 6
antibodies, monoclonal - adverse effects (6) 6
disease-activity (6) 6
double-blind (6) 6
drug therapy, combination (6) 6
injections, subcutaneous (6) 6
necrosis-factor-alpha (6) 6
severity of illness index (6) 6
1506 (5) 5
anemia (5) 5
antirheumatic agents - administration & dosage (5) 5
arthritis, rheumatoid - blood (5) 5
clinical and epidemiological research (5) 5
etanercept (5) 5
prevalence (5) 5
scleroderma (5) 5
therapy (5) 5
adalimumab (4) 4
antirheumatic agents - adverse effects (4) 4
arthritis (4) 4
arthritis, psoriatic - drug therapy (4) 4
arthritis, rheumatoid - complications (4) 4
arthritis, rheumatoid - physiopathology (4) 4
chemistry (4) 4
dose-response relationship, drug (4) 4
gangrene (4) 4
human necessities (4) 4
hygiene (4) 4
improvement (4) 4
inflammation (4) 4
internal medicine (4) 4
medical or veterinary science (4) 4
medicine, general & internal (4) 4
metallurgy (4) 4
organic chemistry (4) 4
peptides (4) 4
preparations for medical, dental, or toilet purposes (4) 4
randomized controlled trials as topic (4) 4
research (4) 4
studies (4) 4
tumor necrosis factor-tnf (4) 4
validation (4) 4
young adult (4) 4
aged, 80 and over (3) 3
anemia - drug therapy (3) 3
anti-tnf (3) 3
antibodies, monoclonal, humanized - therapeutic use (3) 3
arthritis, rheumatoid - pathology (3) 3
association (3) 3
bone-marrow (3) 3
c-reactive protein (3) 3
c-reactive protein - metabolism (3) 3
care and treatment (3) 3
clinical trials (3) 3
controlled-trial (3) 3
drug dosages (3) 3
golimumab (3) 3
hemoglobins - analysis (3) 3
immunoglobulin g - therapeutic use (3) 3
methotrexate - administration & dosage (3) 3
mice (3) 3
monoclonal antibodies (3) 3
pharmaceutical industry (3) 3
phase-iii (3) 3
placebo-controlled trial (3) 3
psoriatic arthritis (3) 3
receptors, tumor necrosis factor - therapeutic use (3) 3
regression analysis (3) 3
rheumatoid factor (3) 3
rheumatoid-arthritis (3) 3
risk (3) 3
spondylitis, ankylosing - drug therapy (3) 3
surveys and questionnaires (3) 3
systemic sclerosis (3) 3
united states - epidemiology (3) 3
american-college (2) 2
anaemia (2) 2
anemia - blood (2) 2
anemia - complications (2) 2
antibodies, monoclonal, humanized - adverse effects (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Annals of the Rheumatic Diseases, ISSN 0003-4967, 06/2014, Volume 73, Issue 6, pp. 990 - 999
Journal Article
Kidney International, ISSN 0085-2538, 12/2013, Volume 84, Issue 6, pp. 1079 - 1089
Journal Article
Journal Article
Journal Article
Clinical Therapeutics, ISSN 0149-2918, 2012, Volume 34, Issue 1, pp. 77 - 90
Abstract Background The pharmacokinetics of golimumab, a human monoclonal antibody that inhibits the activity of tumor necrosis factor α, after a single... 
Internal Medicine | Medical Education | pharmacokinetics | human anti-tumor necrosis factor α monoclonal antibody | methotrexate | C-reactive protein | rheumatoid arthritis | golimumab | Golimumab | Human anti-tumor necrosis factor α monoclonal antibody | Methotrexate | Pharmacokinetics | Rheumatoid arthritis | human anti-tumor necrosis factor alpha monoclonal antibody | CYTOKINES | MULTICENTER | PHASE-III | HUMAN MONOCLONAL-ANTIBODY | INFLIXIMAB TREATMENT | NECROSIS-FACTOR-ALPHA | COMBINATION | THERAPY | DOUBLE-BLIND | PHARMACOLOGY & PHARMACY | Antirheumatic Agents - administration & dosage | Arthritis, Rheumatoid - blood | United States | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Male | Antibodies, Monoclonal - blood | Young Adult | C-Reactive Protein - metabolism | Drug Interactions | Arthritis, Rheumatoid - drug therapy | Injections, Subcutaneous | Antirheumatic Agents - adverse effects | Adult | Female | Drug Therapy, Combination | Antirheumatic Agents - blood | Antibodies, Monoclonal - pharmacokinetics | Treatment Outcome | Biomarkers - blood | Methotrexate - adverse effects | Antibodies, Monoclonal - administration & dosage | Models, Biological | Antirheumatic Agents - pharmacokinetics | Methotrexate - administration & dosage | Aged | Infusions, Intravenous | Arthritis, Rheumatoid - immunology | Tumor Necrosis Factor-alpha - antagonists & inhibitors | Medicine, Experimental | Monoclonal antibodies | Medical research | Rheumatoid factor | Employees | Drug therapy | Drug dosages
Journal Article
Annals of the Rheumatic Diseases, ISSN 0003-4967, 10/2014, Volume 73, Issue 10, pp. 1811 - 1818
Objective Evaluate golimumab in patients with active rheumatoid arthritis (RA) and previous tumour necrosis factor-α (TNF) inhibitor use. Methods Patients... 
Rheumatoid Arthritis | Anti-TNF | DAS28 | MODIFYING ANTIRHEUMATIC DRUGS | MULTICENTER | INADEQUATE RESPONSE | RITUXIMAB | DOUBLE-BLIND | VICE-VERSA | OUTCOMES | RHEUMATOLOGY | ETANERCEPT | INFLIXIMAB | EULAR RECOMMENDATIONS | Antirheumatic Agents - administration & dosage | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antibodies, Monoclonal - therapeutic use | Male | Methotrexate - therapeutic use | Receptors, Tumor Necrosis Factor - therapeutic use | Etanercept | Infliximab | Arthritis, Rheumatoid - drug therapy | Injections, Subcutaneous | Antirheumatic Agents - adverse effects | Adult | Female | Drug Therapy, Combination | Antirheumatic Agents - therapeutic use | Severity of Illness Index | Antibodies, Monoclonal, Humanized - adverse effects | Antibodies, Monoclonal, Humanized - therapeutic use | Drug Administration Schedule | Immunoglobulin G - therapeutic use | Treatment Outcome | Immunoglobulin G - adverse effects | Methotrexate - adverse effects | Antibodies, Monoclonal - administration & dosage | Methotrexate - administration & dosage | Aged | Adalimumab | Drug Substitution | Tumor Necrosis Factor-alpha - antagonists & inhibitors | Usage | Care and treatment | Diagnosis | Rheumatoid arthritis | Necrosis | Studies | Immunoglobulins | Gangrene | TNF inhibitors | Tumor necrosis factor-TNF | Methotrexate | Clinical and Epidemiological Research | 1506
Journal Article
Journal Article